Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sasahira, N
Right arrow Articles by Omata, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sasahira, N
Right arrow Articles by Omata, M
Gut 2005;54:698-702
© 2005 by BMJ Publishing Group Ltd & British Society of Gastroenterology


LIVER

Extrahepatic biliary obstruction after percutaneous tumour ablation for hepatocellular carcinoma: aetiology and successful treatment with endoscopic papillary balloon dilatation

N Sasahira1,*, M Tada1,*, H Yoshida1, R Tateishi1, S Shiina1, K Hirano1, H Isayama1, N Toda1, Y Komatsu1, T Kawabe2, M Omata1

1 Department of Gastroenterology, University of Tokyo, Tokyo, Japan
2 Department of Endoscopy and Endoscopic Surgery, University of Tokyo, Tokyo, Japan

Correspondence to:
Correspondence to:
Dr M Tada
7-3-1 Hongo Bunkyo-Ku, Tokyo, Japan 113-8655; mtada-tky{at}umin.ac.jp

Background and aims: Percutaneous tumour ablation (PTA), such as ethanol injection and radiofrequency ablation, is now recognised as a primary treatment for hepatocellular carcinoma (HCC). Although PTA is a relatively safe procedure, it can cause biliary obstruction as a rare complication. As patients with cirrhosis undergoing surgery or endoscopic retrograde cholangiopancreatography/sphincterotomy have a high mortality rate from bleeding, we adopted the use of endoscopic papillary balloon dilatation (EPBD) in these patients and now report the results. We retrospectively analysed the incidence of biliary obstruction after PTA and the efficacy of treatment with EPBD.

Patients and methods: A total of 1043 patients with HCC were treated by PTA, of whom 538 were treated with transarterial embolisation with up to eight years of follow up.

Results: There were 17 (1.6%) cases of hilar obstruction due to tumour progression and 35 (3.4%) cases of extrahepatic obstruction. Apart from the expected causes of biliary obstruction (haemobilia n = 11, gallstones n = 11, and three miscellaneous causes), we found that 10 patients had obstruction due to biliary casts. This is the first description of biliary casts after percutaneous tumour ablation therapy. Extrahepatic biliary obstruction by procedure related haemobilia occurred within three days of PTA while other causes occurred between 0 and 17 (average 4.9) months. Biliary casts occurred more frequently after ethanol injection than after radiofrequency ablation. EPBD successfully dissipated biliary obstruction in 33 of 35 cases, while two died due to hepatic failure despite successful drainage.

Conclusions: Extrahepatic biliary obstruction is an uncommon complication after PTA for HCC, and can be safely and effectively treated with EPBD, despite impaired liver function.


Abbreviations: PTA, percutaneous tumour ablation; HCC, hepatocellular carcinoma; EPBD, endoscopic papillary balloon dilatation; PEIT, percutaneous ethanol injection therapy; RFA, radiofrequency ablation; EST, endoscopic sphinctectomy; US, ultrasonography; CT, computed tomography; TAE, transarterial embolisation; ERC, endoscopic retrograde cholangiography; ERCP, endoscopic retrograde cholangiopancreatography; {gamma}-GTP, gamma-glutamyl transpeptidase

Keywords: biliary cast; haemobilia; choledocholithiasis; endoscopic papillary balloon dilatation; percutaneous ethanol injection therapy







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 BMJ Publishing Group Ltd & British Society of Gastroenterology